Danny Hsu and Nicola Pozzi on “Tetra-Positive” APS
Danny Hsu, President of THANZ, reposted from Nicola Pozzi on LinkedIn:
”Are we overlooking the “Tetra-Positive” APS patient?
Lupus Anticoagulant (LAC) remains our most valuable predictor of thrombosis, yet it is plagued by analytical interference and false positives.
A compelling new Historical Sketch in JTH by Prof Vittorio Pengo and A/Prof Nicola Pozzi argues it is time to embrace antiprothrombin antibodies to resolve these diagnostic dilemmas.
Key Takeaways for the Lab and Clinic:
- The Rise of “Tetra-Positivity”: Patients positive for LAC, aCL, anti-β2GPI, and aPS/PT (anti-phosphatidylserine/prothrombin) represent a distinct, high-risk phenotype with persistent antibody profiles.
The LAC Surrogate: When LAC results are compromised by acute phase reactants or anticoagulants (heparin/DOACs), aPS/PT testing offers a critical safety net. If aCL, anti-β2GPI, and aPS/PT are all positive, consider the patient high-risk even without a confirmed LAC.
Mechanism Matters (Type I vs. Type II): Not all antibodies are equal. Prothrombin exists in “open” and “closed” forms.
– Type I Antibodies: Recognize the open form (cryptic epitopes). They show weak LAC activity.
– Type II Antibodies: Recognize both forms. These are the drivers of strong LAC activity.
The Future: Keep an eye on aPT-Bio, a new assay using biotinylated recombinant prothrombin that retains native structure, potentially offering higher specificity than current ELISAs.
It is time to refine our risk stratification beyond the standard ‘Triple Positive.”’
Quoting Nicola Pozzi‘s post:
”Hematologists and coagulation enthusiasts—this one’s for you!
Lupus anticoagulant: What is it? How do we measure it?
Why does it matter for Antiphospholipid Syndrome (APS)?
Vittorio Pengo and I revisit this highly debated topic with a historical perspective, and share novel mechanistic insights we uncovered in recent years that could reshape how we understand and test for lupus anticoagulant.
Could it be time to rewrite the coagulation textbook?
Time (and good science) will tell…”
Read the full article in JTH.
Article: Lupus anticoagulant and antiprothrombin antibodies: embracing the future
Authors: Vittorio Pengo, Nicola Pozzi
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS